Literature DB >> 2825415

Reduced mouse neurovirulence of poliovirus type 2 Lansing antigenic variants selected with monoclonal antibodies.

N La Monica1, W J Kupsky, V R Racaniello.   

Abstract

The Lansing strain of poliovirus type 2 is a mouse-adapted virus that induces a fatal paralytic disease in mice after intracerebral inoculation. Our previous results indicated that the mouse-adapted phenotype maps to the Lansing viral capsid. To further define regions of the capsid that are specifically involved in the infection of mice, antigenic variants resistant to neutralization with monoclonal antibodies were selected, and their mouse neurovirulence was studied. The monoclonal antibodies used were directed against antigenic site 1, an immunodominant loop of capsid polypeptide VP1 located on the virion surface. Ten of twenty-two variants selected had lower intracerebral neurovirulence in mice when compared to the parental virus. Four of the ten antigenic variants with reduced neurovirulence were temperature sensitive (ts) for replication in HeLa cells, while the remaining six variants replicated in HeLa cells as well as the parent virus. Two ts+ variants that were studied had a reduced ability to replicate in the mouse brain. There was no difference in the histopathology and pattern of involvement in the central nervous system of one variant compared to the parent virus. In three variants, reduction of neurovirulence correlated with specific amino acid substitutions at positions 100 and 101 of VP1, located within antigenic site 1. The ts phenotype in three variants was associated with a single amino acid deletion at position 105. Virus recovered from the brain of paralyzed mice that had been inoculated with the antigenic variants was characterized to identify the virus causing disease. In most cases, brain isolates resembled the inoculated virus in neurovirulence and amino acid sequence at the antigenic site. Virus recovered from brains of paralyzed mice that had been inoculated with the ts variants was either ts+ or cold sensitive, and had become more neurovirulent. These results suggest that specific amino acid changes within an antigenic site on the virion surface may result in reduction of mouse neurovirulence without affecting viral replication in cultured cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2825415      PMCID: PMC7131194          DOI: 10.1016/0042-6822(87)90136-x

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  Antigenic structure of polioviruses of serotypes 1, 2 and 3.

Authors:  P D Minor; M Ferguson; D M Evans; J W Almond; J P Icenogle
Journal:  J Gen Virol       Date:  1986-07       Impact factor: 3.891

2.  Hemagglutinin-neuraminidase glycoprotein as a determinant of pathogenicity in mumps virus hamster encephalitis: analysis of mutants selected with monoclonal antibodies.

Authors:  A Löve; R Rydbeck; K Kristensson; C Orvell; E Norrby
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

3.  Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies.

Authors:  J O Fleming; M D Trousdale; F A el-Zaatari; S A Stohlman; L P Weiner
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

4.  Attenuated reovirus type 3 strains generated by selection of haemagglutinin antigenic variants.

Authors:  D R Spriggs; B N Fields
Journal:  Nature       Date:  1982-05-06       Impact factor: 49.962

5.  Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing.

Authors:  N La Monica; C Meriam; V R Racaniello
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

6.  Poliovirus infection of cyclophosphamide-treated mice results in persistence and late paralysis: I. Clinical, pathologic, and immunologic studies.

Authors:  B Jubelt; J B Meagher
Journal:  Neurology       Date:  1984-04       Impact factor: 9.910

7.  Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3.

Authors:  D M Evans; P D Minor; G S Schild; J W Almond
Journal:  Nature       Date:  1983 Aug 4-10       Impact factor: 49.962

8.  Pathogenesis of human poliovirus infection in mice. I. Clinical and pathological studies.

Authors:  B Jubelt; G Gallez-Hawkins; O Narayan; R T Johnson
Journal:  J Neuropathol Exp Neurol       Date:  1980-03       Impact factor: 3.685

9.  Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus.

Authors:  B Dietzschold; W H Wunner; T J Wiktor; A D Lopes; M Lafon; C L Smith; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

10.  Neuropeptide-induced hypothermia and the course of central nervous system disease mediated by temperature-sensitive mutants of vesicular stomatitis virus.

Authors:  S C Doll; T C Johnson
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

View more
  20 in total

1.  Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles.

Authors:  F Delpeyroux; E Van Wezel; B Blondel; R Crainic
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Allele-specific adaptation of poliovirus VP1 B-C loop variants to mutant cell receptors.

Authors:  S Liao; V Racaniello
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

3.  Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine.

Authors:  M J Bouchard; D H Lam; V R Racaniello
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

4.  Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak.

Authors:  Jing Shaw; Jaume Jorba; Kun Zhao; Jane Iber; Qi Chen; Festus Adu; Adekunle Adeniji; David Bukbuk; Marycelin Baba; Elizabeth Henderson; Naomi Dybdahl-Sissoko; Sharla McDonald; William C Weldon; Nicksy Gumede; M Steven Oberste; Olen M Kew; Cara C Burns
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

5.  Mapping of attenuating sequences of an avirulent poliovirus type 2 strain.

Authors:  E G Moss; R E O'Neill; V R Racaniello
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Genomic regions of neurovirulence and attenuation in Theiler murine encephalomyelitis virus.

Authors:  M A Calenoff; K S Faaberg; H L Lipton
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

7.  Identification of two determinants that attenuate vaccine-related type 2 poliovirus.

Authors:  R B Ren; E G Moss; V R Racaniello
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

8.  Three-dimensional structure of Theiler virus.

Authors:  R A Grant; D J Filman; R S Fujinami; J P Icenogle; J M Hogle
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

9.  Molecular characterization of mouse-virulent poliovirus type 1 Mahoney mutants: involvement of residues of polypeptides VP1 and VP2 located on the inner surface of the capsid protein shell.

Authors:  T Couderc; J Hogle; H Le Blay; F Horaud; B Blondel
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

10.  Restricted virus replication in the spinal cords of nude mice infected with a Theiler's virus variant.

Authors:  A Zurbriggen; M Yamada; C Thomas; R S Fujinami
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.